-
Je něco špatně v tomto záznamu ?
Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic
O. Löblová,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2006-01-01 do Před 1 rokem
Health Management Database (ProQuest)
od 2006-01-01 do Před 1 rokem
- MeSH
- hodnocení biomedicínských technologií organizace a řízení MeSH
- lidé MeSH
- rozhodování organizační * MeSH
- rozhovory jako téma MeSH
- zdravotní politika * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
This article identifies the interests and policy positions of key health policy stakeholders regarding the creation of a health technology assessment (HTA) agency in the Czech Republic, and what considerations influenced them. Vested interests have been suggested as a factor mitigating the diffusion of HTA bodies internationally. The Czech Republic recently considered and discarded establishing an HTA agency, making it a good case for studying actors' policy positions throughout the policy debates. Findings are based on in-depth, semi-structured expert and elite interviews with 34 key Czech health policy actors, supported by document analysis and extensive triangulation. Findings show that the HTA epistemic community of 'aspiring agents' was the only actor strongly in favor of an HTA body. Payers and the medical device and diagnostics industry were against it; patients and clinicians had no clear preferences. Original decision-makers were in favor but a new minister of health opted for a simpler policy alternative to solve his need for expertise. Existing institutions, policy alternatives and the institutional design of a future HTA body influence domestic actors' preferences for or against an HTA agency. Domestic and international proponents of HTA should give serious thought to their concerns when advocating for HTA bodies.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20015913
- 003
- CZ-PrNML
- 005
- 20201119104907.0
- 007
- ta
- 008
- 201012s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1017/S174413311700024X $2 doi
- 035 __
- $a (PubMed)29108525
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Löblová, Olga $u Visiting Professor,School of Public Policy,Central European University,Budapest,Hungary.
- 245 10
- $a Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic / $c O. Löblová,
- 520 9_
- $a This article identifies the interests and policy positions of key health policy stakeholders regarding the creation of a health technology assessment (HTA) agency in the Czech Republic, and what considerations influenced them. Vested interests have been suggested as a factor mitigating the diffusion of HTA bodies internationally. The Czech Republic recently considered and discarded establishing an HTA agency, making it a good case for studying actors' policy positions throughout the policy debates. Findings are based on in-depth, semi-structured expert and elite interviews with 34 key Czech health policy actors, supported by document analysis and extensive triangulation. Findings show that the HTA epistemic community of 'aspiring agents' was the only actor strongly in favor of an HTA body. Payers and the medical device and diagnostics industry were against it; patients and clinicians had no clear preferences. Original decision-makers were in favor but a new minister of health opted for a simpler policy alternative to solve his need for expertise. Existing institutions, policy alternatives and the institutional design of a future HTA body influence domestic actors' preferences for or against an HTA agency. Domestic and international proponents of HTA should give serious thought to their concerns when advocating for HTA bodies.
- 650 12
- $a rozhodování organizační $7 D003659
- 650 12
- $a zdravotní politika $7 D006291
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a rozhovory jako téma $7 D007407
- 650 _2
- $a hodnocení biomedicínských technologií $x organizace a řízení $7 D013673
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00205332 $t Health economics, policy, and law $x 1744-134X $g Roč. 13, č. 2 (2018), s. 137-161
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29108525 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201012 $b ABA008
- 991 __
- $a 20201119104904 $b ABA008
- 999 __
- $a ok $b bmc $g 1584340 $s 1106081
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 13 $c 2 $d 137-161 $e 20171107 $i 1744-134X $m Health economics, policy, and law $n Health Econ Policy Law $x MED00205332
- LZP __
- $a Pubmed-20201012